Dengue incidence has increased globally, but empirical burden estimates are scarce. Prospective methods are best-able to capture all severities of disease. CYD14 was an observer-blinded dengue vaccine
Estimates exclude the proportion of the incidence envelope attributable to “other pathogens”, because these were not considered in Approach 1 (applied to 60 countries within EURO, AMRO sub-region A, a
*Estimates are based on a Poisson regression model linking weekly mortality with weekly incidence of influenza like illness (average based on 4 A/H1N1–B epidemics and based on 7 A/H3N2 epidemics for s
This dataset is the property of the Khazeni Lab at the Stanford University Department of Pulmonary & Critical Care Medicine. It accompanies the following papers: Patel, Rita B., et al. "Demographic an
aEstimates were weighted using the adjusted sample weight for this sample, WTH1N1. bAssuming no pre-existing seropositivity at baseline. cAge-standardized to the U.S. Census Bureau population estimate
